Intellx

IntellX is a biotechnology company focused on developing next-generation gene therapies for neurodegenerative and neuromuscular diseases caused by RNA toxicity. The company's proprietary Intelligent Gene Therapy (iGT) platform utilizes engineered adeno-associated virus (AAV) vectors to deliver therapeutic payloads that specifically target and neutralize toxic RNA repeats or modulate RNA-binding proteins. Founded as a spin-out from the University of Florida, IntellX is advancing a pipeline of programs for conditions such as Myotonic Dystrophy Type 1 (DM1), ALS, and Frontotemporal Dementia. Their approach aims to address the underlying genetic drivers of these diseases by restoring normal RNA processing and cellular function.